U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07547046) titled 'Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe Preeclampsia' on March 23.
Brief Summary: Severe preeclampsia is a serious pregnancy complication that can lead to severe maternal and fetal outcomes, particularly when blood pressure is not adequately controlled. In France, intravenous labetalol is recommended as the first-line treatment for severe hypertension in preeclampsia. However, in clinical practice, failure to control blood pressure with labetalol is frequently observed, and the factors associated with this lack of response remain poorly understood.
The RELAPSE study is a prospectiv...